Connect with us
European Gaming Congress 2024

Fintech PR

Exyte with robust 6M/2023 results: sales growth of almost 11% to 3.7 billion euros year-on-year



  • Sales increased by 10.6% year-on-year, totaling €3.7 billion
  • Adjusted EBIT grew by 2.5% reaching €207 million, adjusted EBITDA rose by 4.5% to €232 million
  • Order intake amounted to €3.5 billion
  • Sales of around €8.0 billion expected for 2023
  • Exyte signed share purchase agreement to acquire pure media specialist Intega

STUTTGART, Germany, Sept. 5, 2023 /PRNewswire/ — Exyte GmbH (Exyte), a global leader in the design, engineering, and delivery of high-tech facilities, accomplished sound financial results in the first half of fiscal year 2023.

In the first six months of 2023 Exyte recorded a growth in sales of almost 11% to €3.7 billion (6M/2022: €3.4 billion). The order intake totaled €3.5 billion (6M/2022: €4.7 billion). Moreover, an increase in financial earnings was achieved with an adjusted EBIT of €207 million (6M/2022: €202 million) and an adjusted EBITDA of €232 million (6M/2022: €222 million). The adjusted EBIT margin and the adjusted EBITDA margin are slightly below last year’s figures reaching 5.6% and 6.2% respectively. The substantial order backlog of around €6.4 billion ensures Exyte’s future profitable growth.

“In the first half of 2023 we were able to pursue our growth path with solid sales growth and increased financial earnings. Moreover, we were awarded with several key projects all over the world in all our business segments. This shows that Exyte’s strong emphasis on megatrend-driven industries and its customer-centric strategy places the company in an advantageous position to maintain its growth momentum even amidst global economic uncertainties,” says Dr. Wolfgang Büchele, CEO of Exyte.

Financial year 2023: Positive outlook confirmed

“We see that our markets are currently shifting regionally. While semiconductor factories have been built almost exclusively in Asia in recent years, many large-scale projects in the field of semiconductors and battery cells are currently being prepared or are already in implementation especially in the USA and Europe, also driven by government subsidies. This development is reflected in Exyte’s current order and business development,” Büchele continues.

Exyte’s outlook for the remainder of the financial year 2023 is positive, as the company will continuously pursue its ‘Pathway to Ten’ with expected sales of around €8.0 billion by the end of this year and envisaged sales of €10.0 billion by 2027. Order intake is expected around the same high level as in the previous year.


Development of business segments: strong demand in battery cells, high potential in US data center market and additional acquisition for vertical integration

In the first six months of 2023, all business segments contributed to Exyte’s sales growth. The differences in incoming orders are due to specific market developments in the respective industries and are taken into account accordingly in Exyte’s business planning.

In 6M/2023 sales generated in the Advanced Technology Facilities segment grew by around 8% to €3.1 billion year-on-year (6M/2022: €2.9 billion). The business segment is currently executing large-scale semiconductor projects in all geographies. After a particularly strong prior-year period, Exyte achieved an order intake of €2.9 billion (6M/2022: €4.2 billion). Amongst others Exyte has been awarded major semiconductor projects in Germany and the US.

Exyte also continues its success in the business with gigafabs for battery cells. In Europe, Exyte meanwhile is involved in the construction of several new gigafabs. The customers are German vehicle manufacturers, an Asian battery manufacturer and a consortium of vehicle manufacturers with an energy company. In addition, Exyte is in talks with other vehicle manufacturers and technology companies as well as with start-ups working on the next generation of battery cells.

Sales of the Biopharma & Life Sciences business segment slightly increased to €293 million (6M/2022: €291 million). Major projects are currently being implemented in Germany, Malaysia, and Singapore. The segment saw a significant rise in incoming orders of more than 30% reaching €368 million (6M/2022: €283 million). The remarkable growth in order intake is based on large projects in Singapore and Denmark awarded by two leading global healthcare companies.


The Data Centers segment accomplished a record in sales with €251 million, more than doubling last year’s sale (6M/2023: €114 million). This sales development is driven by multiple projects for blue-chip software and technology companies in Denmark, Israel, Malaysia, and Taiwan. The order intake amounted to €124 million (6M/2022: €233 million).

To accelerate the growth of the company’s Data Centers business segment and to meet 2027 revenue targets, Exyte has decided to also enter the US data center market. There, the company wants to take advantage of the local data center industry’s growth. “The data center industry in the US is experiencing rapid growth, with increasing demand for reliable and scalable infrastructure to support digital transformation. We are convinced that Exyte, with its experience and technological know-how, can offer its clients innovative solutions for sustainable and high-performance data centers,” Büchele explains.

The Business Area Technology & Services consisting of several entities providing cleanroom technology, critical equipment for subsystems as well as installation services and offsite manufacturing (OSM) recorded an increase in sales of around 22% to €438 million (6M/2022: €360 million). Moreover, incoming orders rose by close to 9% to €599 million compared to previous year (6M/2022: €552 million). The positive development of CPS Group in the US contributes substantially to this success.

Exyte continues to strengthen its business in the area of mission-critical equipment and installation services. To this end, Exyte recently signed agreements to acquire Intega GmbH, a specialist in high-purity media supply systems. “With the acquisition of Intega, Exyte advances its strategy of vertical integration. The acquisition is the next important step in growing the competence in the area of critical sub-systems for advanced technology facilities, especially for the semiconductor industry. In addition, Intega will act as a nucleus for Exyte’s European service activities,” says Büchele. The transaction is subject to the required approvals by anti-trust authorities.



Key financial figures at a glance




 2023 vs.


Order Intake

€3.5 bn

€4.7 bn

-26.6 %



€3.7 bn

€3.4 bn

+10.6 %

Adjusted EBITDA

€232 m


€222 m

+4.5 %

Adjusted EBITDA Margin

6.2 %

6.6 %


-0.4 PP

Adjusted EBIT

€207 m

€202 m

+2.5 %


Adjusted EBIT Margin

5.6 %

6.0 %

-0.4 PP

* The percentage is calculated based on the values in million.


For more details about our 6M-results 2023 please visit our website.


About Exyte

Exyte is a global leader in the design, engineering, and delivery of ultra-clean and sustainable facilities for high-tech industries. With cutting-edge expertise developed over more than a century, the company serves clients in the sophisticated markets of semiconductors, battery cells, pharmaceuticals, biotechnology, and data centers. Exyte offers a full range of services from consulting to managing the implementation of turnkey solutions with the highest standards in safety and quality to its customers worldwide. Exyte creates a better future by enabling key industries to enhance the quality of modern life. In 2022, the company generated sales of €7.4 billion with around 9,000 employees worldwide.




René Ziegler
Vice President Corporate Communications
& Investor Relations
+49 711 88044606
+49 172 5838786

[email protected]

Logo –

Cision View original content:

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024




STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting


The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision


The following files are available for download:

Invitation to presentation of EQT AB’s Q1 Announcement 2024,c3285895


EQT AB Group


View original content:

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs



  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”


Photo –

Cision View original content to download multimedia:

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update




VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.


BioVaxys Technology Corp. (, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.


Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo –

Cision View original content:

Continue Reading

Latest news